Plain-English translation of NCT07284277 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two treatments for metastatic pancreatic cancer (cancer that has spread beyond the pancreas): modFOLFIRINOX chemotherapy and a device called the NovoTTF-200T system, which uses mild electric fields to target cancer cells. The electric field therapy is non-invasive, meaning it works through patches placed on your skin, with no surgery needed. Researchers want to learn if combining these two treatments is safe and whether it might help patients live longer.
Pancreatic cancer that has spread is very difficult to treat, with very low survival rates. Standard chemotherapy alone has limitations, so doctors are exploring whether adding electric field therapy—which works in a completely different way than drugs—might improve outcomes and help more patients.
You likely qualify if…
You likely don't qualify if…
You would receive modFOLFIRINOX chemotherapy in 14-day cycles while wearing the electric field device. The device uses electrode patches applied to your skin around your abdomen to deliver mild electric pulses to target cancer cells. You would need to attend clinic visits for chemotherapy infusions and monitoring, and researchers would take a small sample (biopsy) from your liver spot to study how the combined treatment affects your cancer. The study involves about 30 patients total across multiple hospital centers.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Spain